- Home
- ASC vs SAGE Comparison
ASC vs SAGE Comparison
Compare ASC & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- SAGE
- Stock Information
- Founded
- ASC 2010
- SAGE 2010
- Country
- ASC Bermuda
- SAGE United States
- Employees
- ASC 936
- SAGE N/A
- Industry
- ASC Marine Transportation
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- SAGE Health Care
- Exchange
- ASC Nasdaq
- SAGE Nasdaq
- Market Cap
- ASC 406.2M
- SAGE 413.9M
- IPO Year
- ASC 2013
- SAGE 2014
- Fundamental
- Price
- ASC $10.14
- SAGE $9.30
- Analyst Decision
- ASC Buy
- SAGE Hold
- Analyst Count
- ASC 3
- SAGE 18
- Target Price
- ASC $13.67
- SAGE $10.06
- AVG Volume (30 Days)
- ASC 565.8K
- SAGE 2.4M
- Earning Date
- ASC 07-30-2025
- SAGE 07-30-2025
- Dividend Yield
- ASC 6.81%
- SAGE N/A
- EPS Growth
- ASC N/A
- SAGE N/A
- EPS
- ASC 2.30
- SAGE N/A
- Revenue
- ASC $373,479,000.00
- SAGE $47,404,000.00
- Revenue This Year
- ASC N/A
- SAGE $102.21
- Revenue Next Year
- ASC N/A
- SAGE $43.01
- P/E Ratio
- ASC $4.41
- SAGE N/A
- Revenue Growth
- ASC N/A
- SAGE N/A
- 52 Week Low
- ASC $8.32
- SAGE $4.62
- 52 Week High
- ASC $23.16
- SAGE $13.47
- Technical
- Relative Strength Index (RSI)
- ASC 55.26
- SAGE 78.92
- Support Level
- ASC $9.45
- SAGE $6.44
- Resistance Level
- ASC $10.60
- SAGE $9.33
- Average True Range (ATR)
- ASC 0.35
- SAGE 0.26
- MACD
- ASC 0.07
- SAGE 0.33
- Stochastic Oscillator
- ASC 67.61
- SAGE 98.98
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.